BioSniper
ZH
Toggle language
Open menu
Phase 2 Readout
~quarter
Phase 2 Readout: agent-797
December 31, 2026
Company
MiNK Therapeutics, Inc. (INKT)
Drug
agent-797
Indication
severe acute lung injury and respiratory distress
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.
Start Free
Full Calendar
INKT Overview
PDUFA Dates
Phase 3 Readouts
Phase 2 Readout: agent-797 — INKT Phase 2 Readout | BioSniper